Literature DB >> 9712732

Sequences surrounding the Src-homology 3 domain of phospholipase Cgamma-1 increase the domain's association with Cbl.

L J Graham1, B A Stoica, M Shapiro, K E DeBell, B Rellahan, J Laborda, E Bonvini.   

Abstract

SH3 domains are protein modules that interact with proline-rich polypeptide fragments. Cbl is an adapter-like protein known to interact with several SH3 domains, including the PLCgamma1 SH3 domain and the Grb2 amino terminal SH3 domain. Here we explore whether sequences surrounding the PLCgamma1 SH3 domain core sequence (aa.796-851) can affect the binding to Cbl, a target used as a prototypical ligand. Consistent with previous reports, our results demonstrated a weak binding of Cbl to GST fusion proteins that strictly encompass the structural core of the PLCgamma1 SH3 domain but a high-avidity binding to the Grb2 amino-terminal SH3 domain. Inclusion of amino acids immediately flanking the PLCgamma1 SH3 core domain, however, substantially increased binding of Cbl to a level comparable to that of the Grb2 amino-terminal SH3 domain. The interaction of this extended PLCgamma1 SH3 domain fusion protein with Cbl was shown to depend entirely upon the interaction of the domain with a proline-rich motif in Cbl, ruling out the possibility that amino acids adjacent to the core SH3 domain of PLCgamma1 provide independent Cbl binding. These data suggest that sequences surrounding the SH3 domain of PLCgamma1 may contribute to or stabilize the association of the domain with the target protein, thus increasing its binding efficiency. Copyright 1998 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9712732     DOI: 10.1006/bbrc.1998.9177

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  8 in total

1.  Pleiotropic contributions of phospholipase C-gamma1 (PLC-gamma1) to T-cell antigen receptor-mediated signaling: reconstitution studies of a PLC-gamma1-deficient Jurkat T-cell line.

Authors:  B J Irvin; B L Williams; A E Nilson; H O Maynor; R T Abraham
Journal:  Mol Cell Biol       Date:  2000-12       Impact factor: 4.272

2.  Structural Determinants of the Gain-of-Function Phenotype of Human Leukemia-associated Mutant CBL Oncogene.

Authors:  Scott A Nadeau; Wei An; Bhopal C Mohapatra; Insha Mushtaq; Timothy A Bielecki; Haitao Luan; Neha Zutshi; Gulzar Ahmad; Matthew D Storck; Masashi Sanada; Seishi Ogawa; Vimla Band; Hamid Band
Journal:  J Biol Chem       Date:  2017-01-12       Impact factor: 5.157

3.  Cbl-b is a novel physiologic regulator of glycoprotein VI-dependent platelet activation.

Authors:  James L Daniel; Carol A Dangelmaier; Sripal Mada; Lorena Buitrago; Jianguo Jin; Wallace Y Langdon; Alexander Y Tsygankov; Satya P Kunapuli; Archana Sanjay
Journal:  J Biol Chem       Date:  2010-04-16       Impact factor: 5.157

4.  Functional independence and interdependence of the Src homology domains of phospholipase C-gamma1 in B-cell receptor signal transduction.

Authors:  K E DeBell; B A Stoica; M C Verí; A Di Baldassarre; S Miscia; L J Graham; B L Rellahan; M Ishiai; T Kurosaki; E Bonvini
Journal:  Mol Cell Biol       Date:  1999-11       Impact factor: 4.272

5.  Identification of Novel Crk-associated Substrate (p130Cas) Variants with Functionally Distinct Focal Adhesion Kinase Binding Activities.

Authors:  Joerg Kumbrink; Shefali Soni; Barbara Laumbacher; Barbara Loesch; Kathrin H Kirsch
Journal:  J Biol Chem       Date:  2015-03-24       Impact factor: 5.157

6.  Interactions between Cdc42 and the scaffold protein Scd2: requirement of SH3 domains for GTPase binding.

Authors:  Edward Wheatley; Katrin Rittinger
Journal:  Biochem J       Date:  2005-05-15       Impact factor: 3.857

Review 7.  Mutant T cell lines as model systems for the dissection of T cell antigen receptor signaling pathways.

Authors:  R T Abraham
Journal:  Immunol Res       Date:  2000       Impact factor: 4.505

8.  c-Cbl inhibits angiogenesis and tumor growth by suppressing activation of PLCγ1.

Authors:  R D Meyer; D Husain; N Rahimi
Journal:  Oncogene       Date:  2011-01-17       Impact factor: 9.867

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.